Icagen/McNeil’s ICA-17043 Is Lead Candidate To Be Second Sickle Cell Drug On Market
This article was originally published in The Pink Sheet Daily
Executive Summary
The compound is poised to begin Phase III; J&J subsidiary McNeil entered a U.S. co-development and commercialization partnership with innovator Icagen for the oral once-daily chronic treatment in June. The orphan drug has fast-track status at FDA.